Christina Scherer

Christina Scherer is VP and Head, Early Portfolio Management at Acrivon Therapeutics. She has over 20 years of experience leading drug discovery and development programs in biotech and nonprofit settings. Prior to Acrivon, she was the Senior Director of Product and Portfolio Development at Anokion US and Kanyos Bio, where she led preclinical and clinical product development teams for a novel tolerance-inducing platform. Prior to this, Christina was the Director of Anti-infectives Discovery at the Broad Institute of MIT and Harvard, where she directed interdisciplinary project teams to discover and optimize novel small molecule therapeutics for multiple infectious diseases, including malaria, gram-negative bacteria, and Clostridium difficile. She obtained more than $10M in grants to support these efforts, and managed relationships with external pharmaceutical and nonprofit partners to advance drug development efforts. Prior to the Broad Institute, Christina held positions at Illumigen Biosciences and Kineta in Seattle, WA. Christina received her B.A. in Biology from Amherst College and her PhD. in Molecular and Cellular Biology from MIT.